London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Paps.. how much is Amryt up since its 24p listing price % wise?
I've forgotten the splits breakdown.
Thanks..
Good to see you're still around Bermudashorts. Hope you're well?
I held my AMYT through all the deramps and took profits over last couple of weeks for a solid multibag. I was thinking of getting into Open Orphan but it has left the station already. I'm looking at other medical investments if you have any tips...
Krystal going higher and higher?
Its seems like everything at Amryt is at a snail's pace.
Nasdaq slowly but surely making higher highs..
AMYT one *looks* like it is shaping for another decent lift up to 3s now. It looks like consolidation and floor are firmly in at 1.8 levels. Agree? Remember this went to 2.5 intraday on the last jump so we are nicely set up at 2.2s to start moving again.
Possibly directly north from these level or a quick revisit to 1.88 for a double bottom momentum steep climb.
Either way, I suspect there has been enough in the pipeline flow to get this into the early 3s in less than two quarters.
This should be;
$1B in < 4 yrs.
$4B in < 10 yrs.
As a holder of the CVR's, I wasn't quite sure of the conditions attached. Found this in Amryt's half-yearly report. In case anyone is interested.
The terms of the CVRs are as follows:
• The total CVR payable is up to US$85,000,000
• This is divided into three milestones which are related to the success of FILSUVEZ (the Group’s lead development
asset, currently in Phase 3 clinical trials)
• FDA approval
o US$35,000,000 upon FDA approval
o 100% of the amount due if approval is obtained before December 31, 2021, with a sliding scale on a linear
basis to zero if before July 1, 2022
15
• EMA approval
o US$15,000,000 upon EMA approval
o 100% of the amount due if approval is obtained before December 31, 2021, with a sliding scale on a linear
basis to zero if before July 1, 2022
• Revenue targets
o US$35,000,000 upon FILSUVEZ revenues exceeding US$75,000,000 in any 12-month period prior to June 30,
2024
• Payment can, at the Board’s discretion, be in the form of either:
o 120-day loan notes (effectively cash), or
o Shares valued using the 30 day / 45-day VWAP
That's very good news for UK vaccine development. It's great to be a pioneer but It does beg the question of how long it will be before other countries follow suit? I imagine there are plenty of poorer countries where relatively small financial incentives would attract volunteers.
Sad but true. However, Krystal are using HSV-1 as the delivery mechanism for their EB trials.
He's about to hit the big time..
https://www.gov.uk/government/news/worlds-first-coronavirus-human-challenge-study-receives-ethics-approval-in-the-uk
Interesting, yet sad, find, Bermuda,
A bitter blow for sickle cell disease sufferers today with the announcement from Bluebird Bio that they have suspended their phase I/II and phase III trials for their gene therapy LentiGlobin after 2 patients have been diagnosed with cancer. They are investigating whether the lentviral vector used may be the cause. Hopefully it will transpire that these cases weren't treatment related and the trials will resume but this comment is interesting:-
'The new cancer cases, however, will refocus attention on a possible cancer risk inherent with Bluebird’s gene therapy — and also raise concerns for any gene therapy company that uses re-engineered lentiviruses as part of its treatments.'
Amryt of course have gone down the route of using HPAE - a synthetic polymer to deliver their EB gene therapy AP103 and from outset have highlighted the potential safety advantages this brings over other EB gene therapies using lentiviral vectors.
https://www.statnews.com/2021/02/16/bluebird-suspends-studies-of-sickle-cell-gene-therapy-following-cancer-diagnoses-in-two-more-treated-patients/
An exciting year beckons for AMYT, as it steadily releases positive RNSes - and an increasing reputation to deliver its strategy on realising value accretion.
FDA APPROVES FIRST-IN-CLASS EVKEEZA™ (EVINACUMAB-DGNB) FOR PATIENTS WITH ULTRA-RARE INHERITED FORM OF HIGH CHOLESTEROL
DJframboise, All the best in your other investments.
Yep good luck djframboise - hope we all get to cash in those CVRs
Cheers bud, nice to pass your way.
Needed funds urgently today so Amryt was the solution. Sad to sell after 4 years but have made great returns and still have the CVR's hopefully to look forward to. Finances permitting, may well be back but wish you all well and hopefully onwards and upwards.
GLA DJF
Bermuda, Agreed - happy with the slow strategy to building a solid base for the company.
Prop,
Who knows? Jo Wiley and the BOD have played a strategic blinder here and have already taken the market cap from about £38m to £380m in the space of a couple of years. Building blocks quietly being put in place to continue along that trajectory.
Bermuda, Hard work going on in the background - soon to be a billion-pound company.
Yes and without the fanfare which is always a good sign.
Yet more good news from Amryt with Israel now added to the global reach for both Lojuxta and Myalept and Canada for Juxtapid. Pretty sure that Myalept is already available in Canada.
Also. it looks like some clinical news is expected over the coming weeks with a phase II trial for Lojuxta/Juxtapid in familial chylomicronemia syndrome (FCS) due to to produce data in Q1. Also due this quarter is feedback from the FDA on the clinical development pathway for Myalepta in Partial Lipodystrophy.
Amryt just getting on with the job in hand - good stuff.
Don't be showing your ignorance, its not nice, son.
Nope,but I have in the past traded small share amounts to test liquidity as I dont pay trading fees.
Its a level of trading way above your pay grade!
Did you just buy three shares Bronx ?
Its like something only you would do.